Rigel Pharmaceuticals Analyst Ratings
Rigel Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/02/2023 | 1027.82% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/03/2023 | 1027.82% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 04/03/2023 | 50.38% | Piper Sandler | → $2 | Assumes | → Neutral |
| 03/09/2023 | 125.56% | Citigroup | $2 → $3 | Maintains | Buy |
| 03/08/2023 | 1027.82% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 12/02/2022 | — | Citigroup | Upgrades | Neutral → Buy | |
| 11/04/2022 | 125.56% | BMO Capital | $4 → $3 | Maintains | Outperform |
| 08/18/2022 | 1027.82% | HC Wainwright & Co. | $7 → $15 | Maintains | Buy |
| 08/17/2022 | 50.38% | Piper Sandler | $1 → $2 | Maintains | Neutral |
| 06/09/2022 | 125.56% | BMO Capital | $7 → $3 | Maintains | Outperform |
| 06/09/2022 | -6.02% | B. Riley Securities | $4 → $1.25 | Maintains | Neutral |
| 06/09/2022 | -39.85% | Citigroup | $7 → $0.8 | Downgrades | Buy → Neutral |
| 06/08/2022 | 426.32% | HC Wainwright & Co. | $11 → $7 | Maintains | Buy |
| 06/08/2022 | — | Cantor Fitzgerald | Downgrades | Overweight → Neutral | |
| 03/23/2022 | 200.75% | B. Riley Securities | → $4 | Initiates Coverage On | → Neutral |
| 02/18/2021 | 727.07% | HC Wainwright & Co. | $8 → $11 | Maintains | Buy |
| 11/09/2020 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 08/06/2020 | 501.5% | Citigroup | $7 → $8 | Maintains | Buy |
| 05/27/2020 | 351.13% | JP Morgan | $7 → $6 | Maintains | Overweight |
| 12/09/2019 | 501.5% | BMO Capital | $11 → $8 | Maintains | Outperform |
| 11/15/2019 | 275.94% | Cantor Fitzgerald | $7 → $5 | Maintains | Overweight |
| 09/26/2019 | 426.32% | JP Morgan | → $7 | Assumes | → Overweight |
| 08/27/2018 | 539.1% | Citigroup | → $8.5 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/02/2023 | 1027.82% | HC Wainwright & Co. | → 15 美元 | 重申 | 购买 → 购买 |
| 05/03/2023 | 1027.82% | HC Wainwright & Co. | → 15 美元 | 重申 | → 购买 |
| 04/03/2023 | 50.38% | 派珀·桑德勒 | → 2 美元 | 假设 | → 中立 |
| 03/09/2023 | 125.56% | 花旗集团 | 2 美元 → 3 美元 | 维护 | 购买 |
| 03/08/2023 | 1027.82% | HC Wainwright & Co. | → 15 美元 | 重申 | → 购买 |
| 12/02/2022 | — | 花旗集团 | 升级 | 中性 → 买入 | |
| 2022 年 4 月 11 日 | 125.56% | BMO 资本 | 4 美元 → 3 美元 | 维护 | 跑赢大盘 |
| 08/18/2022 | 1027.82% | HC Wainwright & Co. | 7 美元 → 15 美元 | 维护 | 购买 |
| 08/17/2022 | 50.38% | 派珀·桑德勒 | $1 → $2 | 维护 | 中立 |
| 2022 年 9 月 6 日 | 125.56% | BMO 资本 | 7 美元 → 3 美元 | 维护 | 跑赢大盘 |
| 2022 年 9 月 6 日 | -6.02% | B. 莱利证券 | 4 美元 → 1.25 美元 | 维护 | 中立 |
| 2022 年 9 月 6 日 | -39.85% | 花旗集团 | 7 美元 → 0.8 美元 | 降级 | 买入 → 中性 |
| 06/08/2022 | 426.32% | HC Wainwright & Co. | 11 美元 → 7 美元 | 维护 | 购买 |
| 06/08/2022 | — | 坎托·菲茨杰拉德 | 降级 | 超重 → 中性 | |
| 03/23/2022 | 200.75% | B. 莱利证券 | → 4 美元 | 启动覆盖开启 | → 中立 |
| 2021 年 2 月 18 日 | 727.07% | HC Wainwright & Co. | 8 美元 → 11 美元 | 维护 | 购买 |
| 2020 年 9 月 11 日 | — | 摩根大通 | 降级 | 超重 → 中性 | |
| 08/06/2020 | 501.5% | 花旗集团 | 7 美元 → 8 美元 | 维护 | 购买 |
| 05/27/2020 | 351.13% | 摩根大通 | 7 美元 → 6 美元 | 维护 | 超重 |
| 12/09/2019 | 501.5% | BMO 资本 | 11 美元 → 8 美元 | 维护 | 跑赢大盘 |
| 11/15/2019 | 275.94% | 坎托·菲茨杰拉德 | 7 美元 → 5 美元 | 维护 | 超重 |
| 2019 年 9 月 26 日 | 426.32% | 摩根大通 | → 7 美元 | 假设 | → 超重 |
| 08/27/2018 | 539.1% | 花旗集团 | → 8.5 美元 | 启动覆盖开启 | → 购买 |
What is the target price for Rigel Pharmaceuticals (RIGL)?
锐佳制药（RIGL）的目标价格是多少？
The latest price target for Rigel Pharmaceuticals (NASDAQ: RIGL) was reported by HC Wainwright & Co. on August 2, 2023. The analyst firm set a price target for $15.00 expecting RIGL to rise to within 12 months (a possible 1027.82% upside). 9 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年8月2日公布了锐佳制药（纳斯达克股票代码：RIGL）的最新目标股价。这家分析公司将目标股价定为15.00美元，预计RIGL将在12个月内升至15.00美元（可能上涨1027.82％）。去年有9家分析公司公布了评级。
What is the most recent analyst rating for Rigel Pharmaceuticals (RIGL)?
锐佳制药（RIGL）的最新分析师评级是多少？
The latest analyst rating for Rigel Pharmaceuticals (NASDAQ: RIGL) was provided by HC Wainwright & Co., and Rigel Pharmaceuticals reiterated their buy rating.
锐佳制药（纳斯达克股票代码：RIGL）的最新分析师评级由HC Wainwright & Co. 提供，锐佳制药重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Rigel Pharmaceuticals (RIGL)?
锐佳药业（RIGL）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rigel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rigel Pharmaceuticals was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与锐佳制药的高管和客户交谈以及听取财报电话会议）后得出股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。锐佳制药公司的最后一次评级是在2023年8月2日提交的，因此您应该预计下一个评级将在2024年8月2日左右公布。
Is the Analyst Rating Rigel Pharmaceuticals (RIGL) correct?
分析师对锐佳药业（RIGL）的评级是否正确？
While ratings are subjective and will change, the latest Rigel Pharmaceuticals (RIGL) rating was a reiterated with a price target of $0.00 to $15.00. The current price Rigel Pharmaceuticals (RIGL) is trading at is $1.33, which is within the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的锐佳药业（RIGL）评级得到了重申，目标股价为0.00美元至15.00美元。锐佳制药（RIGL）目前的交易价格为1.33美元，在分析师的预测区间内。